ライフサイエンスコーパス: bone marrow transplant

1 pthatic pneumonia syndrome (IPS) following a bone marrow transplant.

2 41 years in patients who had not received a bone marrow transplant.

3 but were normalized in mice that received a bone marrow transplant.

4 s to improve outcomes in patients undergoing bone marrow transplant.

5 the individuals were successfully treated by bone marrow transplant.

6 in the peripheral blood of NHP recipients of bone marrow transplant.

7 mphoid organs of recipients of an allogeneic bone marrow transplant.

8 al treatments, such as radiation therapy and bone marrow transplant.

9 perimental parent C57BL/6-->CB6F1 allogeneic bone marrow transplant.

10 and Functional Assessment of Cancer Therapy-Bone Marrow Transplant.

11 obilization in preparation for an autologous bone marrow transplant.

12 ng repopulation of the immune system without bone marrow transplant.

13 (CML) after treatment with IFN or allogeneic bone marrow transplant.

14 injury after myeloablative chemotherapy and bone marrow transplant.

15 s hematopoietic recovery in mice receiving a bone marrow transplant.

16 mprove the homing of HSC after an autologous bone marrow transplant.

17 rotein, used as an immunostimulant following bone-marrow transplant.

18 TBI and were able to prevent engraftment of bone marrow transplants.

19 d is predicated on >40 years of success with bone marrow transplants.

20 mismatched) or female (sex-matched, control) bone marrow transplants.

21 aematopoietic cells following congenic mouse bone marrow transplants.

22 patients with hematological malignancies and bone marrow transplants.

23 rmed in Bambi(+/+) mice receiving Bambi(-/-) bone marrow transplants.

24 e cortex were found in HD mice that received bone marrow transplants.

25 t clinical data from 21 patients following a bone marrow transplant, 13 of which progress to idiopath

26 In comparison with allele-matched bone-marrow transplants, 5-year leukaemia-free survival

27 do not develop efficiently in the thymus of bone marrow transplanted adult tgepsilon26 mice, which h

28 lovirus (CMV) infection following allogeneic bone marrow transplant (allo-BMT) is controlled by donor

29 t-chain fatty acids (SCFAs) after allogeneic bone marrow transplant (allo-BMT).

30 ibute to activation of APCs after allogeneic bone marrow transplant (alloBMT), we examined whether th

31 IV susceptibility in circulating T cells via bone marrow transplants allowed some individuals with HI

32 o syngeneic wild-type mice via Tgfbr2(Myeko) bone marrow transplant and can be rescued in Tgfbr2(Myek

33 rts of 121 pediatric patients who received a bone marrow transplant and subsequently required mechani

34 nfarct fibroblasts using lineage tracing and bone marrow transplants and a robust marker for cardiac

35 ss has led to effective therapies, including bone marrow transplants and gene therapy, that would hav

36 m the lungs and by rejection of incompatible bone marrow transplants and in vitro by cytolysis of YAC

37 Secondary bone marrow transplants and integration site analysis co

38 y observed in recipients of solid organs and bone marrow transplants and is associated with increased

39 hat CHQ may impair rejection of incompatible bone marrow transplants and other functions mediated by

40 Patients who received mismatched bone marrow transplants and those who received mismatche

41 pe bone marrow-transplanted mice, ROCK2(+/-) bone marrow-transplanted and ROCK2(-/-) bone marrow-tran

42 marrow and its differentiated progeny after bone marrow transplant, and several mouse hematopoietic

43 patients (10.3%) proceeded to an allogeneic bone marrow transplant, and the overall response rate wa

44 fection, leukemia, lymphoma, solid organ and bone marrow transplants, and inherited immune deficienci

45 A combination of pair-feeding, bone marrow-transplant, and microglial ablation implicat

46 application of hematopoietic stem cells for bone-marrow transplant, and further elucidation of homin

47 y detected by histology in tumors taken from bone marrow transplanted animals, they were spatially is

48 In this study, a bone marrow transplant approach was used to investigate

49 acute phase response proteins at the time of bone marrow transplant are highly likely to develop IPS

50 r and establishment of treatment followed by bone marrow transplant are important to survival.

51 Bone marrow transplants are an important therapeutic too

52 b; 1 died 6 months after a matched unrelated bone marrow transplant as a result of undefined encephal

53 a complete remission received an allogeneic bone marrow transplant as consolidation.

54 Furthermore, in a murine bone marrow transplant assay, genetic deficiency in RSK2

55 Bone marrow transplant assays and examination of steady-

56 C numbers and premature exhaustion in serial bone marrow transplant assays.

57 toGvHD occurs spontaneously after autologous bone marrow transplant (autoBMT) in the absence of CsA i

58 ociated multifactorial disease of allogeneic bone marrow transplant (BMT) -induced graft-vs.-host dis

59 logenous leukemia (AML) and those undergoing bone marrow transplant (BMT) are at greatest risk for co

60 locus were nonrandomly assigned to receive a bone marrow transplant (BMT) by using oral busulfan (16

61 FNgamma and IL-6 polymorphisms in 80 sibling bone marrow transplant (BMT) donor/recipient pairs.

62 ntinued over several months before and after bone marrow transplant (BMT) from his RSV-immune father.

63 ion-negative patients received an allogeneic bone marrow transplant (BMT) in first complete remission

64 We used a murine syngeneic bone marrow transplant (BMT) model, in which administrat

65 fatal myeloproliferative disease in a murine bone marrow transplant (BMT) model, whereas T/T(F) cause

66 ase (aGVHD) in 2 different murine allogeneic bone marrow transplant (BMT) models.

67 NF-alpha receptors as donors in well-defined bone marrow transplant (BMT) models.

68 Using our syngeneic bone marrow transplant (BMT) mouse model, BMT mice with

69 We previously reported that murine bone marrow transplant (BMT) neutrophils overexpress cyc

70 all the hematopoietic tissues of 16 primary bone marrow transplant (BMT) recipient mice and 14 secon

71 L challenge in both syngeneic and allogeneic bone marrow transplant (BMT) recipients at both early an

72 driven responses, was that rearrangements in bone marrow transplant (BMT) recipients exhibited much l

73 ociated T-cell deficiency seen in allogeneic bone marrow transplant (BMT) recipients.

74 However, there are unusually high bone marrow transplant (BMT) rejection rates in these pa

75 graft tolerance in mice receiving allogeneic bone marrow transplant (BMT) with minimal conditioning.

76 ed States; yet, the only curative therapy, a bone marrow transplant (BMT), is seldom applied.

77 We found that cerebral engraftment by bone marrow transplant (BMT)-derived wild-type or EP2(-/

78 CML at various time points after allogeneic bone marrow transplant (BMT).

79 of systemic lupus erythematosus, were given bone marrow transplants (BMT) at 20 wk of age using MHC-

80 Using cross bone marrow transplants (BMT) between young and old fema

81 We performed bone marrow transplants (BMT) from green fluorescent pro

82 trated that SHIP(-/-) mice accept allogeneic bone marrow transplants (BMT) without significant acute

83 Bone marrow-transplanted (BMT) XSCID dogs not only engra

84 One-half of bone-marrow transplant (BMT) and stem-cell transplant re

85 A baboon bone-marrow transplant (BMT) was performed in an attempt

86 ukemia (CML) underwent unrelated donor (URD) bone marrow transplants (BMTs) facilitated by the Nation

87 consolidation chemotherapy and an autologous bone marrow transplant, but eventually died 22 months af

88 KGF-/- recipients of syngeneic or allogeneic bone marrow transplant, but using KGF-/- mice as a donor

89 ells (HSCs) are the therapeutic component of bone marrow transplants, but finding immune-compatible d

90 Intestinal IL-22 was produced after bone marrow transplant by IL-23-responsive innate lympho

91 tment of tumor-bearing Tg/NCD mice or Tg/NCD bone marrow transplanted C3H mice (Tg/NCD-C3H) resulted

92 cts that can be corrected with an allogeneic bone marrow transplant can theoretically also be treated

93 ther specific subsets of cells in allogeneic bone marrow transplants can effectively treat the BCL(1)

94 xty-three percent of 24 NCs collected from a bone marrow transplant center contained biofilms compris

95 signaling in PcP-related lung injury, murine bone marrow transplant chimeras of wild-type, C57BL6/J,

96 We exposed bone marrow transplant chimeric mice to hypoxia and trea

97 Using gfp(+) bone marrow-transplant chimeric mice, we demonstrate tha

98 s assessed with European Group for Blood and Bone Marrow Transplant criteria.

99 Secondary bone marrow transplants demonstrated continued equivalen

100 the adult brain 1 to 6 months after an adult bone marrow transplant demonstrates a remarkable plastic

101 d that myeloablative irradiation followed by bone marrow transplant-derived microglia engraftment, ra

102 Ldlr(-/-) mice with a Nur77(-/-)-deficient bone marrow transplant developed 2.1-fold larger atheros

103 ients who responded to therapy who underwent bone marrow transplant did not show any benefit from thi

104 Unfortunately, unless combined with a bone marrow transplant, disease relapse is frequent.

105 suggested, and indicate that improvement of bone marrow transplant efficiency may be possible in the

106 diated in vivo LTbetaR stimulation following bone marrow transplant enhances initial thymus recovery

107 In a green fluorescent protein bone marrow transplant experiment we found green fluores

108 However, bone marrow transplant experiments and cell type-specifi

109 Murine bone marrow transplant experiments demonstrate that JAK2

110 Mechanistically, bone marrow transplant experiments demonstrate that TBI

111 Reciprocal bone marrow transplant experiments identified that loss

112 We conducted bone marrow transplant experiments in which we transferr

113 Bone marrow transplant experiments revealed that Fpr2/3(

114 Bone marrow transplant experiments revealed that leukocy

115 Reciprocal bone marrow transplant experiments showed that Sostdc1 r

116 not affect leukocyte functions in vitro, and bone marrow transplant experiments suggest that host Akt

117 -resident macrophages by lineage tracing and bone marrow transplant experiments.

118 HSCs fail to compete with wild-type HSCs in bone marrow transplant experiments.

119 Bone marrow-transplant experiments using IFN-gammaR-/- m

120 s in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) score relative to base

121 the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) were received from 109

122 in individuals who had previously received a bone marrow transplant for hematological disorders.

123 s erythematosus, and conditioning regimen of bone marrow transplant for Hurler's syndrome.

124 nza B infection in a child who had undergone bone marrow transplant for X-linked severe combined immu

125 accinia virus, followed by combined skin and bone marrow transplant from a BALB/c donor.

126 osis and (2) a female patient who received a bone marrow transplant from a male donor and subsequentl

127 In the female recipient of a bone marrow transplant from a male donor, 12.4% of the m

128 adequate immune reconstitution despite prior bone marrow transplant from a parent.

129 Allogeneic bone marrow transplant from an HLA-matched sibling can h

130 d in nontransgenic SCID mice that received a bone marrow transplant from GFP-expressing SCID mice.

131 Rats status post 5/6 nephrectomy underwent bone marrow transplant from human placental alkaline pho

132 An HLA-identical bone marrow transplant from the mother led patient 1 to

133 1(-/-) rats was almost completely rescued by bone marrow transplanted from FHH controls.

134 Bone marrow transplants from Arg2-deficient mice did not

135 Control mice that received bone marrow transplants from control mice had an influx

136 inflammation and liver damage in mice given bone marrow transplants from Cyp27a1(-/-) mice and place

137 In Ldlr(-/-) mice that received bone marrow transplants from Cyp27a1(-/-) mice, lysosome

138 ion was inhibited, irradiated mice receiving bone marrow transplants from heterozygous GFP+ mice reve

139 H pylori-infected control mice that received bone marrow transplants from LysMCre/Smo(KO) mice.

140 brain samples from females who had received bone marrow transplants from male donors.

141 ported by experiments in which recipients of bone marrow transplants from SR-uPA+/0 donors but not no

142 onto Fgfbp1 GFP-knock-in reporter hosts and bone marrow transplants from the GFP-reporter model into

143 FVIII(null) mice that received bone marrow transplants from wild-type donors were still

144 ite numerous reports of GBS in recipients of bone marrow transplants, GBS has rarely been reported in

145 ." Ablation of the immune system followed by bone marrow transplant has been shown to cure experiment

146 re, predictors for 5-year mortality included bone marrow transplant (hazard ratio, 3.66; 95% CI, 2.26

147 reover, generating chimeric mice via UPRT(+) bone marrow transplants identifies immune versus niche s

148 u/CY conditioning, for HLA-identical sibling bone marrow transplants in children with ALL.

149 Based on reciprocal bone marrow transplants in conjunction with assessment o

150 have been utilized extensively in allogeneic bone marrow transplants in order to purge the allograft

151 ould potentially overcome the limitations of bone marrow transplants, including graft rejection and t

152 years after the first successful allogeneic bone marrow transplants, infection remains the most comm

153 was achieved using CD11c-Cre x Tcf4(-/flox) bone marrow transplanted into Ldlr(-/-) mice.

154 We report here that following syngeneic bone marrow transplants into lethally irradiated C57BL6

155 We conclude that immune tolerance to bone marrow transplants involves clonal deletion, and to

156 experiments involving H. felis infection of bone marrow transplanted irradiated mice have suggested

157 suggest that one mechanism for relapse after bone marrow transplant is acquired tolerance of allogene

158 opoietic stem cell transplantation (HSCT, or bone marrow transplant), is common even after transplant

159 An isolated vascularized bone marrow transplant (iVBMT) model was developed to st

160 An isolated vascularized bone marrow transplant (iVBMT) model was previously deve

161 In bone marrow-transplanted K19-kras mice that progressed t

162 s transformation in Ba/F3 cells and a murine bone marrow transplant leukemia model.

163 show that in both the steady-state and after bone marrow transplant, lymphotoxin beta receptor (LTbet

164 LTbeta-null mice that received WT bone marrow transplants maintained mutant hair phenotype

165 flammation in patients undergoing autologous bone marrow transplant may reduce the subsequent develop

166 res: Functional Assessment of Cancer Therapy-Bone Marrow Transplant, Mental Health Inventory, occupat

167 In the bone marrow transplant mice, double immunofluorescent st

168 cent studies have shown that in radiated and bone marrow transplanted mice, bone marrow-derived cells

169 of a polymeric IL-8 delivery system into GFP bone marrow-transplanted mice revealed that localized IL

170 +/-) bone marrow-transplanted and ROCK2(-/-) bone marrow-transplanted mice showed substantially less

171 Compared with wild-type bone marrow-transplanted mice, ROCK2(+/-) bone marrow-tr

172 arger atherosclerotic lesions than wild-type bone marrow-transplanted mice.

173 -expressing Tregs over time in an allogeneic bone marrow transplant model and demonstrated colocaliza

174 major histocompatibility complex-mismatched bone marrow transplant model in which graft-versus-host

175 We established a murine bone marrow transplant model of the inv(16) in which wil

176 Employing a bone marrow transplant model to compartmentalize TLR4 si

177 Further, we used a bone marrow transplant model to determine the influence

178 In this study, we used the mouse bone marrow transplant model to further explore the role

179 uce a myeloproliferative disease in a murine bone marrow transplant model, but are not sufficient to

180 Using a bone marrow transplant model, we also demonstrated that

181 Using a syngeneic murine bone marrow transplant model, we demonstrate that vaccin

182 Using a bone marrow transplant model, we previously showed that

183 ferase-expressing CIK cells in an allogeneic bone marrow transplant model.

184 les that cause aggressive T-ALLs in a murine bone marrow transplant model.

185 w chimerism can be produced in a mouse-->rat bone marrow transplant model.

186 reat ALL-bearing mice using a minor mismatch bone marrow transplant model.

187 gnificant prolongation of survival in murine bone marrow transplant models of FGFR3 TDII-induced pre-

188 hough cytokine levels are elevated in murine bone marrow transplant models of leukemia using tyrosine

189 In murine bone marrow transplant models, PD-L1 expression on host

190 y and generates a PV-like phenotype in mouse bone marrow transplant models.

191 duce a myeloproliferative syndrome in murine bone marrow transplant models.

192 ) or respiratory (odds ratio, 1.56) reasons, bone marrow transplant (odds ratio, 1.53), previous ICU

193 at GHS promoted better thymic engraftment in bone marrow transplant of SCID mice.

194 or alpha(V)beta(3), we performed reciprocal bone marrow transplants on wild-type and beta3(-/-) mice

195 replacement therapy, or more effectively by bone marrow transplant or HSC gene therapy (HSC-GT).

196 from five females who had received either a bone-marrow transplant or an allogeneic mobilised periph

197 status (P =.04), and early disease status at bone marrow transplant (P =.05) were associated with sup

198 CMV and human herpesvirus type 6 (HHV-6) in bone marrow transplant patients (causing marrow suppress

199 that it is possible to estimate dd-cfDNA in bone marrow transplant patients that are unrelated or th

200 Only among bone marrow transplant patients were overall survival (O

201 report GBS in organ transplant patients and bone marrow transplant patients, both of whom have iatro

202 ective in certain high-risk patients such as bone marrow transplant patients, few studies have focuse

203 nocompromised individuals, such as organ and bone marrow transplant patients.

204 ated with severe human disease in kidney and bone marrow transplant patients.

205 lyomavirus (BKPyV) affects mostly kidney and bone marrow transplant patients.

206 nsplant patients and hemorrhagic cystitis in bone marrow transplant patients.

207 the severity of graft-versus-host disease in bone marrow transplant patients.

208 wo novel GII.4 variants in immunocompromised bone marrow transplant patients.

209 provide a functional cure, as observed in a bone marrow transplant performed with hematopoietic stem

210 Bone marrow transplants performed on wild-type and KSR1(

211 t of lung injury in the early periautologous bone marrow transplant period.

212 Bone marrow transplants point to altered stellate cell f

213 Hex bone marrow transplant recipient mice also develop hemat

214 isolated from brain abscess material from a bone marrow transplant recipient.

215 her had leukemia (n = 14) or were allogeneic bone marrow transplant recipients (n = 13).

216 emia after months of apparent cure in recent bone marrow transplant recipients and an immediately-tre

217 in immunocompromised individuals, including bone marrow transplant recipients and cancer and AIDS pa

218 Bone marrow transplant recipients and single-ventricle p

219 TLs for adoptive immunotherapy of HLA-A*0201 bone marrow transplant recipients from 200 mL donor bloo

220 pecific DNA in the peripheral blood of islet/bone marrow transplant recipients of same sex cynomolgus

221 phomas is seen in solid organ transplant and bone marrow transplant recipients receiving immunosuppre

222 number of features that distinguish them as bone marrow transplant recipients that must be understoo

223 From an initial cohort of 12 bone marrow transplant recipients who received marrow fr

224 prognosis generally is poor among pediatric bone marrow transplant recipients who subsequently requi

225 kinase (SR-uPA(+/0) mice) and of SR-uPA(+/0) bone marrow transplant recipients, and we used bioinform

226 During CMV reactivation in bone marrow transplant recipients, KIR(+)CD56(+) T cells

227 ncluding patients with AIDS, solid organ and bone marrow transplant recipients, patients with leukemi

228 mmunodeficiency virus-positive patients, and bone marrow transplant recipients, were tested for cytom

229 ding of the impact of respiratory viruses on bone marrow transplant recipients.

230 ansplant outcomes in NHP combined kidney and bone marrow transplant recipients.

231 potential clinical uses of FTY in allogeneic bone marrow transplant recipients.

232 e a partially penetrant, long-latency AML in bone marrow transplant recipients.

233 (PBLs), and whole blood (WB) from allogeneic bone marrow transplant recipients.

234 ansplant patients or hemorrhagic cystitis in bone marrow transplant recipients.

235 suppressed individuals, including kidney and bone marrow transplant recipients.

236 Bone marrow transplants reconstituted mice with T cells,

237 Following bone marrow transplant, recovery of a normal peripheral

238 The databases of the International Bone Marrow Transplant Registry (IBMTR) and the European

239 9 to 1998 and were reported to International Bone Marrow Transplant Registry (IBMTR) or Autologous Bl

240 white patients reported in the International Bone Marrow Transplant Registry (IBMTR), 30% of 341 MDS

241 ant recipients reported to the International Bone Marrow Transplant Registry (IBMTR).

242 chronic phase provided by the International Bone Marrow Transplant Registry and the National Marrow

243 1968 to 1996, reported to the International Bone Marrow Transplant Registry and/or National Marrow D

244 r results were reported to the International Bone Marrow Transplant Registry by 144 participating ins

245 published data beyond that from the European Bone Marrow Transplant Registry exist.

246 ed with those from 509 similar International Bone Marrow Transplant Registry patients who underwent t

247 5 and 1999 and reported to the International Bone Marrow Transplant Registry were included.

248 From a large European bone marrow transplant registry, a birds' eye view of st

249 one of 82 centers reporting to the European Bone Marrow Transplant Registry.

250 1989 to 1997, reported to the International Bone Marrow Transplant Registry.

251 3 centers participating in the International Bone Marrow Transplant Registry.

252 62) were recruited through the International Bone Marrow Transplant Registry/Autologous Blood and Mar

253 mune and neurodegenerative states, organ and bone marrow transplant rejection, and tumor response to

254 a data set from the Center for International Bone Marrow Transplant Research (CIBMTR) registry databa

255 ed with 151 matched Center for International Bone Marrow Transplant Research controls.

256 develop myeloid and lymphoid cells received bone marrow transplants resulting in donor-derived micro

257 Subsequent bone marrow transplants revealed the contribution of bot

258 the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT) questionnaire, w

259 observations, we found that both genetic and bone marrow-transplanted SCD mice had greater mortality

260 and safe method for immunosuppression in the bone marrow transplant setting.

261 lograft rejection in MHC-identical solid and bone marrow transplant settings.

262 ransplantation conditioning regimen prior to bone marrow transplant significantly increased the risk

263 Bone marrow transplant studies and quantitation of macro

264 Bone marrow transplant studies point to altered macropha

265 Furthermore, bone marrow transplant studies reveal that these improve

266 n unexpected finding was noted in allogeneic bone marrow transplant studies using IL-7 receptor null

267 Here we use sex-mismatched bone marrow transplant subjects to show that smooth musc

268 vestigations of animals and short-term human bone marrow transplants suggest that bone marrow can rep

269 Bone marrow transplants suggest that the absence of beta

270 ased bone mass could partially be rescued by bone marrow transplants supporting our hypothesis that r

271 survivors and siblings participating in the Bone Marrow Transplant Survivor Study (BMTSS) completed

272 Using resources offered by the Bone Marrow Transplant Survivor Study (BMTSS), we evalua

273 Reciprocal bone marrow transplants that involved both wild-type and

274 Bone marrow-transplanted TLR2 chimeric mice were generat

275 In addition, chimeric mice were generated by bone marrow transplant to limit expression of IL7Ralpha

276 Here, we use bone marrow transplants to generate mice chimeras that e

277 Here, we compare CD13 wild-type and null bone marrow-transplanted tumor-bearing mice to show that

278 units supplying cooled bottled water to the bone marrow transplant unit.

279 a contaminated drinking water dispenser in a bone marrow transplant unit.

280 semiallogeneic T cells, long-term after the bone marrow transplant using G-Neutrophils, were confirm

281 and cancer cells in leukemia patients after bone marrow transplants, using a system of six delay dif

282 METHODS AND Using genetic lineage tracing or bone marrow transplant, we found no evidence for collage

283 virus cases occurring in children undergoing bone marrow transplant, we undertook norovirus genome se

284 By using bone marrow transplants, we showed that MRP14 deficiency

285 tients aged 2-70 years receiving their first bone marrow transplant were eligible for inclusion in th

286 g System score, and presence or absence of a bone marrow transplant were found between groups.

287 Patients with hematologic malignancy or bone marrow transplant were more likely to develop a com

288 A total of 960 recipients of solid organ or bone marrow transplants were identified from Veterans He

289 Allogeneic bone marrow transplants were performed between B6 (H2(b)

290 Reciprocal bone marrow transplants were performed to test the impor

291 had received chemotherapy, radiation, and a bone marrow transplant, were analyzed.

292 traperitoneally thioglycollate in Abcg1(-/-) bone marrow-transplanted, Western diet-fed, Ldlr-deficie

293 Treatment is bone marrow transplant, which is effective in treating t

294 from stem cells residing in the bone marrow, bone marrow transplanted wild-type mice were treated wit

295 d human leukocyte antigen-matched kidney and bone marrow transplant with lead follow-up time of more

296 However, bone marrow transplants with mature donor T cells can in

297 is during zymosan-induced peritonitis, using bone marrow transplants with transgenic mice deficient i

298 We performed bone marrow transplants with wild-type CD45.1 and CD45.2

299 low-density lipoprotein receptor (LDLR) were bone-marrow transplanted with NLRP3-deficient, ASC (also

300 ontaminating cancerous cells from autologous bone marrow transplants without perturbing the engraftme